Jacobs Levy Equity Management
BMRN icon

Jacobs Levy Equity Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Jacobs Levy Equity Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-52,071
Closed -$3.66M – 944
2024
Q3 		$3.66M Buy
+52,071
New +$4.35M 0.01% 496
2021
Q3 		– Sell
-128,121
Closed -$10.7M – 1037
2021
Q2 		$10.7M Sell
128,121
-98,590
-43% -$7.82M 0.07% 280
2021
Q1 		$17.1M Buy
226,711
+31,602
+16% +$2.58M 0.13% 197
2020
Q4 		$17.1M Buy
195,109
+3,736
+2% +$296K 0.15% 167
2020
Q3 		$14.6M Buy
+191,373
New +$19.4M 0.15% 153
2019
Q3 		– Sell
-104,970
Closed -$8.99M – 922
2019
Q2 		$8.99M Buy
104,970
+41,856
+66% +$3.58M 0.12% 208
2019
Q1 		$5.61M Buy
+63,114
New +$5.85M 0.08% 309
2018
Q1 		– Sell
-4,450
Closed -$397K – 1003
2017
Q4 		$397K Sell
4,450
-220
-5% -$19.1K 0.01% 797
2017
Q3 		$435K Buy
+4,670
New +$413K 0.01% 729
2015
Q4 		– Sell
-24,320
Closed -$2.56M – 811
2015
Q3 		$2.56M Sell
24,320
-76,255
-76% -$10.2M 0.05% 309
2015
Q2 		$13.8M Buy
100,575
+70,600
+236% +$8.75M 0.26% 127
2015
Q1 		$3.73M Buy
+29,975
New +$3.18M 0.06% 268

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
EIM
Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Jacobs Levy Equity Management's BMRN Position: Q4 2024 in Review

Jacobs Levy Equity Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2024, closing a stake of 52,071 shares — an estimated $3.66M sold.

Jacobs Levy Equity Management first reported a position in BMRN in Q1 2015 and held it in 12 quarters. The position peaked at $17.1M in Q1 2021. 543 funds tracked by Wall St. Rank hold BMRN as of Q4 2024.

  • Jacobs Levy Equity Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 52,071 BioMarin Pharmaceuticals shares in Q4 2024, an estimated $3.66M.
  • Jacobs Levy Equity Management first reported a position in BioMarin Pharmaceuticals in Q1 2015 and held it in 12 quarters.
  • Jacobs Levy Equity Management's BioMarin Pharmaceuticals position peaked at $17.1M in Q1 2021.
  • 543 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2024.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2024, filed 14 Feb 2025.